

Substitute for form 1449A/PTO

ATTORNEY'S DO. NO.  
032775-047APPLICATION NO.  
09/847,355INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

APPLICANT

Morris et al.

#6

FILING DATE

May 3, 2001

GROUP

1636



## U.S. PATENT DOCUMENTS

Examiner Initials	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication (MM-DD-YYYY)
	Number	Kind Code (if known)		

## FOREIGN PATENT DOCUMENTS

Examiner Initials	Foreign Patent Document		Country	Date of Publication (MM-DD-YYYY)	Translation	
	Number	Kind Code (if known)			Yes	No

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				
DL	Lichty, B.D., et al., Abstract "Identification of vesicular stomatitis virus as a leukemolytic agent", <i>Blood</i> 96 (11): 213b (2000).				
DL	Seth, P., et al., "Adenovirus-mediated gene transfer to human breast tumor cells: An approach-for-cancer gene therapy and bone marrow purging", <i>Cancer Research</i> 56 (6): 1346-1351 (1996).				
DL	Stojdl, D.F., et al., "Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus", <i>Nature Medicine</i> 6 (7): 821-825 (2000).				
DL	Wu, A.G. et al., "Bone marrow purging of neuroblastoma by attenuated multimmatured herpes simplex virus", <i>Proceedings of the American Association for Cancer Research Annual</i> 39: 605 (1998).				
DL	Wu, A, et al., "Biological purging of breast cancer cells using an attenuated replication-competent herpes simplex virus in human hematopoietic stem cell transplantation", <i>Cancer Research</i> 61 (7): 3009-3015 (2001).				
Examiner Signature	<i>David Lamberton</i>		Date Considered	8/15/02	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.